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Abstract
The L-type amino acid transporter-1 (LAT-1) has been
associated with tumor growth. Using cDNA micro-
arrays, overexpression of LAT-1 was found in 87.5%
(7/8) of esophageal adenocarcinomas relative to
12 Barrett’s samples (33% metaplasia and 66% dys-
plasia) and was confirmed in 100% (28/28) of Barrett’s
adenocarcinomas by quantitative reverse transcription
polymerase chain reaction. Immunohistochemistry
revealed LAT-1 staining in 37.5% (24/64) of esophageal
adenocarcinomas on tissue microarray. LAT-1 also
transports the amino acid–related chemotherapeutic
agent, melphalan. Two esophageal adenocarcinoma
and one esophageal squamous cell line, expressing
LAT-1 on Western blot analysis, were sensitive to
therapeutic doses of melphalan (P < .001). Simulta-
neous treatment with the competitive inhibitor, BCH
[2-aminobicyclo-(2,1,1)-heptane-2-carboxylic acid], de-
creased sensitivity to melphalan (P < .05). In addition,
confluent esophageal squamous cultures were less
sensitive to melphalan (P < .001) and had a decrease in
LAT-1 protein expression. Tumors from two esoph-
ageal adenocarcinoma cell lines grown in nude mice
retained LAT-1 mRNA expression. These results
demonstrate that LAT-1 is highly expressed in a
subset of esophageal adenocarcinomas and that
Barrett’s adenocarcinoma cell lines expressing LAT-1
are sensitive to melphalan. LAT-1 expression is also re-
tained in cell lines grown in nude mice providing a mo-
del to evaluate melphalan as a chemotherapeutic agent
against esophageal adenocarcinomas expressing
LAT-1.
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Introduction
The uptake of amino acids is essential for a number of
cellular functions including protein synthesis, metabolism,
and cell growth. The L-type amino acid transporter-1
(LAT-1) transports large, branched-chain and aromatic,
neutral amino acids, including several essential amino
acids, and is a member of the sodium-independent amino acid
transport system L [1]. Unlike the system L isoform LAT-2,
which is more widely expressed, LAT-1 is normally expressed
in fetal liver, bone marrow, brain, placenta, and testes [2].
LAT-1 has also been reported to be highly expressed in
cultured cells and malignant tumors, and is important in allow-
ing continuous growth [2–5]. All tumor cell lines examined by
Yanagida et al. [5] expressed LAT-1 including bladder, small
cell lung, cervical, and teratocarcinoma cells. In addition,
Ohkame et al. [6] showed a significant relationship between
the expression of LAT-1 and the size of hepatic nodules in a
model for metastatic rat colon carcinoma.
A remarkable characteristic of the LAT-1 transporter is its
broad substrate selectivity that allows it to transport amino
acid– related compounds including L-DOPA, thyroid hor-
mones, gabapentin, and the chemotherapeutic agent,
melphalan [1,7–11]. In a Xenopus oocyte expression system,
100 mM melphalan was able to inhibit 50% of the LAT-1–
mediated uptake of [14C]phenylalanine [12]. LAT-1 upregula-
tion in tumor cells has been proposed as one of the major
routes in the uptake of melphalan into the cell [5]. In addition,
the level of system L amino acid transporter activity in tumor
cells has been reported to be correlated with sensitivity to
melphalan [13,14]. To our knowledge, melphalan has not been
previously evaluated as a chemotherapeutic agent in the
treatment of esophageal adenocarcinoma.
Over the past two decades, the incidence of esophageal
adenocarcinoma has increased greatly, whereas the 5-year
survival remains low at <10% [15,16]. Although esophagec-
tomy remains the primary means of treatment, there is an
urgent need for both novel therapies and early detection
methods. Based on initial cDNA microarray studies suggesting
that LAT-1 is overexpressed in Barrett’s adenocarcinoma, the
present study was undertaken to characterize the expression
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of LAT-1 in esophageal adenocarcinomas and in the precur-
sor Barrett’s mucosa. Due to its ability to transport melpha-
lan, we also hypothesized that Barrett’s adenocarcinoma cell
lines expressing LAT-1 would be sensitive to therapeutic
doses of melphalan and that this sensitivity would be de-




Written consent and approval of the Institutional Review
Board were obtained to collect specimens from patients
undergoing esophagectomy at the University of Michigan
Medical Center (Ann Arbor, MI). Patients in this study had no
preoperative radiation or chemotherapy. Specimens were
transported to the laboratory in Dulbecco’s modified Eagle’s
medium (DMEM; Life Technologies Inc., Carlsbad, CA) on
ice. A portion of each sample was frozen in ornithine carba-
moyltransferase (OCT) compound (Miles Inc., Elkhart, IN)
for cryostat sectioning. The remainder was frozen in liquid
nitrogen and stored at 80jC.
Cell Lines
Nine esophageal cell lines were used in this study. OE33
[17], Seg-1, Bic-1, and Flo-1 were derived from esophageal
adenocarcinomas and have been described previously [18].
H00-T, L65-T, and BA1 also originated from esophageal
adenocarcinomas, whereas S23-B was derived from
Barrett’s metaplasia following immortalization with E6/E7
retroviral infection. BA1 was kindly provided by Dr. Rutten
(Oregon Health and Science University, Portland, OR). Het-
1A is an esophageal squamous cell line immortalized by
SV40 infection [19]. All cell lines were grown in DMEM (Life
Technologies Inc.) supplemented with 10% fetal bovine
serum (FBS; Atlanta Biologicals, Norcross, GA) and 1%
penicillin/streptomycin/fungizone (Life Technologies Inc.) at
37jC in 5% carbon dioxide/95% air.
Tumor Cell Injection in Nude Mice
Bic-1 and Seg-1 cells (5  106 cells) were injected sub-
cutaneously into the flank of athymic nude mice at two
separate sites. The tumors were excised 4 weeks after
injection and frozen at 80jC for later analysis.
RNA Extraction and cDNA Microarray
RNA samples were stored at 80jC. Total RNA
was extracted from tissue samples (four samples each for
Barrett’s, low-grade and high-grade dysplasia, and stage I
and II tumors). Prior to RNA isolation, the tissues were either
homogenized using a precooled mortar and pestle in a dry
ice ethanol bath, or disrupted using a Mixer Mill MM 300
(Retsch GmbH and Co. KG, Haan, Germany). Total RNA
was isolated from tumor and Barrett’s esophagus samples
using the Totally RNA kit for isolation of total cellular RNA
(Ambion, Austin, TX) according to the manufacturer’s
instructions. Poly A+ RNA was purified using the Oligotex
mRNA midi kit (Qiagen Inc., Valencia, CA). Each polyA+
RNA sample was linearly amplified using the protocol
detailed by Van Gelder et al. [20] with minor modifications.
The amplified RNA was reverse-transcribed using MMLV
reverse transcriptase, 0.05 pg/ml oligo-dT primer (21mer),
1  first strand buffer, 0.03 U/ml RNase inhibitor, 500 mM
dATP, 500 mM dGTP, 500 mM dTTP, 40 mM dCTP, and
40 mM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Bio-
sciences Inc., Piscataway, NJ). Specific yeast control
polyA+ RNA were included as quantitative controls. After
incubation at 37jC for 2 hours, each reaction sample (one
with Cy3 and another with Cy5 labeling) was treated with
2.5 ml of 0.5 M sodium hydroxide and incubated for
20 minutes at 85jC to stop the reaction and degrade the
RNA. Probes were purified using two successive CHROMA
SPIN 30 gel filtration spin columns (Clontech, Palo Alto,
CA). After combining, both reaction samples were ethanol-
precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium
acetate, and 300 ml of 100% ethanol. The probe was then
dried to completion using a SpeedVAC (Thermo Savant,
Holbrook, NY) and resuspended in 14 ml of 5  SSC/0.2%
sodium dodecyl sulfate (SDS).
The hybridization of the labeled probes to the cDNA
arrays was performed at Incyte Genomics (St. Louis, MO).
Briefly, the probe mixture was heated to 65jC for 5 minutes,
aliquoted onto the cDNA microarray, and covered with a
1.8-cm2 coverslip. The arrays were incubated for 6.5 hours
at 60jC and washed for 10 minutes at 45jC in high-
stringency wash buffer (1  SSC, 0.1% SDS) and three
times for 10 minutes each at 45jC in low-stringency wash
buffer (0.1  SSC) before drying. Differential gene expres-
sion was detected using a microscope equipped with an
Innova 70 mixed gas 10-W laser (Coherent Lasers, Santa
Clara, CA) capable of generating spectral lines at 488 nm
for excitation of Cy3 and 632 nm for excitation of Cy5. The
differential expression values were quality-controlled inter-
nally and reported as percent fold increase over a pool of
Barrett’s esophagus samples. A filtering algorithm was used
to select genes that were overexpressed in adenocarci-
nomas or dysplastic Barrett’s mucosa when compared to
Barrett’s metaplasia samples. Only those genes with over-
expression at least twice that of Barrett’s metaplasia and
in a minimum of two samples were considered significant.
Quantitative Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
The level of LAT-1 gene expression was determined by
real-time quantitative PCR on an ABI 7900 HT sequence
detection system (Applied Biosystems, Foster City, CA).
Briefly, the primer sets were designed using Primer 3
(Whitehead Institute/MIT Center for Genome Research,
Cambridge, MA) and synthesized by Operon Inc. (Houston,
TX). The LAT-1 forward and reverse primers were 5V-
CAACCCAGCCCAGTGTAAC-3 V and 5V-GACACCC-
TCTGCCGAGTAAT-3V. The glucuronidase-b (GUS-B)
forward and reverse primers were 5V-CAGTGCCCATTCC-
TATGCCATCGTG-3V and 5V-ACCTGGACCAGGTTGCT-
GAT-3V. cDNA was generated using the ABI Taqman
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Reverse Transcription Reagents kit (Applied Biosystems)
with RNA extracted from 12 Barrett’s metaplasia, 4 low-
grade and 10 high-grade dysplasia, and 15 stage I and 13
stage II esophageal adenocarcinoma samples. Gene ex-
pression was analyzed using the SYBR green real-time
quantitative PCR assay (Applied Biosystems). The standard
reaction mix included 350 nM of each primer and 9.1 ml of a
1/10 dilution of the cDNA. GUS-B was used to normalize
input RNA concentrations. SYBR green dye detects PCR
products by measuring the increase in fluorescence caused
by the binding of SYBR green dye to the minor groove of
double-stranded DNA. Significant differences of relative
quantification were determined using the 2(-delta delta
C(T)) method [21]. These data are represented as the fold
increases in LAT-1 gene expression normalized to the
endogenous reference gene (GUS-B) relative to the Barrett’s
esophagus control pool.
RT-PCR
RNA samples were treated with DNase I (Promega,
Madison, WI), and 2 mg of total RNA was reverse tran-
scribed using reverse transcriptase (Life Technologies Inc.)
with (dT)18 and random hexamers in a 20-ml solution of
10 mM of each dNTP, 5  reaction buffer, 0.1 M DTT,
and RNasin (Promega). PCR amplification of LAT-1 was
performed using 1.5 ml of the cDNA products with the
forward and reverse primers 5V-TCCCGCGGTGCTGACT-
GAG-3V and 5V-GTTGTGGTGGGTTGTGCTTGAAAA-3V.
GAPDH PCR amplification was performed using the pri-
mers 5 V-AGTCCATGCCATCACTGCCA-3 V and 5 V-
GGTGTCGCTGTTGAAGTCAG-3V. The following cycling
parameters were used: initial denaturing for 2.5 minutes
at 95jC and then 40 seconds at 95jC, 1 minute at 59jC,
and 1 minute at 72jC for 35 cycles. The PCR products
were resolved on a 1% agarose gel with ethidium bromide
(0.25 mg/ml), and the products were visualized using UV
transillumination.
Immunohistochemistry and Tissue Microarray (TMA)
A TMA was constructed, as previously described [22],
with formalin-fixed, paraffin-embedded tissues from 70
patients including 64 tumor, 8 lymph node metastases,
8 dysplastic Barrett’s mucosa, and 11 nondysplastic Barrett’s
metaplasia samples. Normal esophagus was also included.
Immunohistochemical staining was performed on the
DAKO Autostainer (DAKO, Carpinteria, CA) using DAKO
LSAB+ and diaminobenzadine (DAB) as the chromagen. All
samples were included on a single TMA and were stained for
the same amount of time. Dewaxed and rehydrated sections
of the TMA at 4-mm thickness were labeled with LAT-1
antibody (mouse monoclonal antibody, 1:200 dilution;
Cosmo Bio Co., Tokyo, Japan) or ASCT-1 antibody (rabbit
polyclonal antibody, 1:1000; Chemicon International, Teme-
cula, CA). Microwave citric acid epitope retrieval for 20
minutes was used for both antibodies. Slides were lightly
counterstained with hematoxylin. Each sample was then
scored using a scale of 0, 1, 2, or 3 corresponding to absent,
light, moderate, or intense staining.
Protein Extraction and Western Blot Analysis
Protein was extracted from cell pellets and tissue samples
using NP-40 detergent lysis buffer and protease inhibitor
cocktail (20 ml/1 ml NP-40; Sigma-Aldrich Corp., St. Louis,
MO). Fiftymicrograms of proteins fromeach samplewas then
mixed with one fifth the volume of sample buffer [0.35 M
Tris–Cl, pH 6.8, 10% SDS, 30% glycerol, 9.3% dithiothreitol
(DTT), and 0.175 mM bromophenol blue] and heat-denatured
byboiling for 6minutes.Extractswerestoredat80jCuntil use.
The proteins were then electrophoresed in a 10% SDS
polyacrylamide gel along with Benchmark Prestained Protein
Ladder (Life Technologies Inc.). The separated proteins were
transferred to polyvinylidene difluoride membranes (Immobi-
lon-P, Millipore, Bedford, MA) overnight at 4jC and then
incubated with a blocking solution (0.05% Tween 20, 50 mM
Tris, pH 8.0, 150mMNaCl, and 5% powdered nonfat milk) for
1 hour. The membranes were incubated with either a 1:500
dilution of mouse anti–LAT-1 antibody (Cosmo Bio Co.) or a
1:1000 dilution of rabbit anti–ASCT-1 antibody (Chemicon
International) for 1 hour. Secondary antibodies used were
1:5000 dilutions of either a goat anti–mouse (Southern
Biotechnology Associates, Birmingham, AL) or anti–rabbit
antibody (Vector Laboratories Inc., Burlingame, CA) for an
additional hour. Primary antibody binding was visualized
using an enhanced chemiluminescence kit (Pierce, Rock-
ford, IL) and Hyperfilm-MP (Amersham International, Buck-
inghamshire, UK). b-Actin expression was determined with a
1:1000 dilution of an anti –b-actin monoclonal antibody
(Abcam, Cambridge, UK) and used as a loading control.
Treatment of Cell Cultures with Melphalan
Cell culture treatments were performed as previously
described [12,23–25]. Briefly, once cell cultures reached
70% confluence, they were trypsinized and transferred to
six-well plates. Each well was plated with 2  105 cells and
incubated for 24 hours in DMEM (Life Technologies Inc.) with
10% FBS (Atlanta Biologicals) and 1% penicillin/streptomy-
cin/fungizone (Life Technologies Inc.). For experiments on
confluent cultures, 5  105 cells were plated per well and
incubated for an average of 3 days until cultures were
confluent. Cells were then treated with 5 to 25 mMmelphalan
(Sigma-Aldrich Corp., St. Louis, MO) dissolved in acidified
ethanol (40:1), as previously described [12,23,24]. Control
cultures were treated with an equivalent amount of acidified
ethanol. After 4 hours, the treatment medium was removed
and replaced with fresh media. Cells were allowed to grow for
48 hours before being trypsinized and centrifuged at 6000
rpm. All experiments were repeated in triplicate.
To evaluate responses to the system L competitive inhib-
itor, BCH (Sigma-Aldrich Corp.), 70% confluent cultures
were treated with 0 to 10 mM BCH in 1 N NaOH [2,14]. Five
micromolar melphalan was added 10 minutes after BCH,
whereas control cultures received an equivalent dose
of NaOH and melphalan. Cells were treated with BCH/
melphalan for 4 hours after which treatment medium was
removed and replaced with fresh media. Cells were then
allowed to grow for 48 hours before being trypsinized and
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centrifuged. Cell pellets were resuspended in phosphate-
buffered saline and counted using a hemocytometer. The
ratio of live to dead cells was determined using 0.5% trypan
blue exclusion and a hemocytometer as previously de-
scribed [26,27]. All experiments were repeated in triplicate.
Statistical Analysis
Statistical analysis was performed by comparing the
experimental group to control cultures using a two-sided
Student’s t-test on Microsoft Excel v. X for the Macintosh.
Results
Expression of LAT-1 mRNA in Barrett’s Mucosa and
Adenocarcinoma
When compared to the level of expression in Barrett’s
metaplasia, cDNA microarray analysis revealed 2- to 16-
fold overexpression of LAT-1 mRNA in seven of eight
tumor samples including both stage I and stage II tumors.
These results were confirmed by quantitative RT-PCR in
100% (28/28) of esophageal adenocarcinomas relative to
12 samples of Barrett’s metaplasia with 3- to 38-fold over-
expression (Figure 1). There were no differences in ex-
pression between Barrett’s metaplasia and dysplasia.
Analysis of Primary Tissues Using TMA
Staining of LAT-1 protein on the esophageal TMA is
summarized in Table 1. LAT-1 staining was present in
37.5% (24/64) of esophageal adenocarcinomas (Figure 2,
C and D). Light staining was found in Barrett’s metaplasia
(1/11), dysplasia (1/8), and a normal esophageal sample
(Figure 2, A and B). However, the most intense staining
was found in tumor tissues of which 21.9% (14/64) showed
moderate or intense staining (Table 2; Figure 2, C and D).
Of the lymph node metastases, 50% (4/8) were positive for
LAT-1 staining.
Western Blot Analysis of Tumor Tissues and Esophageal
Cell Lines
Western blot analysis confirmed the TMA results show-
ing high LAT-1 protein expression (predicted molecular
mass, 55 kDa) in D48-T tumor and moderate amounts in
S92-T (Figure 3A). Smaller amounts were found in tumors
C55-T, S43-T, S36-T, and S68-T, and a sample of Bar-
rett’s metaplasia D48-B. In contrast, normal esophagus
expressed low levels of LAT-1 protein. Nine esophageal
cell lines, including seven lines derived from esophageal
adenocarcinoma, one from Barrett’s mucosa, and an
esophageal squamous cell line, were then evaluated for
LAT-1 protein expression by Western blot analysis. As
shown in Figure 3B, all nine esophageal cell lines showed
expression of LAT-1 protein.
Analysis of ASCT-1 mRNA and Protein Expression
During the course of these experiments, the amino acid
transporter, ASCT-1, a transporter of small neutral amino
acids, was also evaluated. ASCT-1 has been reported by
Younes et al. [28] to be overexpressed in esophageal
adenocarcinomas. However, on cDNA microarray analysis,
no difference was found for ASCT-1 mRNA expression in
esophageal adenocarcinoma compared to nondysplastic
and dysplastic Barrett’s mucosa. On Western blot analysis,
ASCT-1 protein was expressed in esophageal adenocarci-
noma cell lines Bic-1, Flo-1, Seg-1, and H00-T (Figure 3C ).
However, similar levels of expression were also seen in
S23-B derived from Barrett’s mucosa. Although staining for
ASCT-1 protein was seen in 96.9% (62/64) of esophageal
adenocarcinoma samples on TMA immunohistochemistry
(Table 2; Figure 2H ), staining was also seen in all Barrett’s
metaplasia and dysplasia samples (Table 2; Figure 2,
F and G). In fact, the majority of Barrett’s metaplasia
(54.5%) and dysplasia (63.6%) samples showed intense
staining. Staining was also found in a sample of normal
esophagus (Figure 2E ). Thus, in contrast to LAT-1, ASCT-1
does not appear to be overexpressed in esophageal
adenocarcinoma.
Figure 1. Quantitative RT-PCR confirmed overexpression of LAT-1 in 15
stage I and 13 stage II esophageal adenocarcinomas relative to 12 Barrett’s
metaplasia samples. The median level of gene expression for each sample
type was normalized against the median expression level of the pooled
Barrett’s metaplasia samples. (Boxed areas represent the first to third
quartile. Crossbars indicate maximum and minimum values, and Xs
represent median levels.) HGD = high-grade dysplasia.
Table 1. Immunohistochemical Analysis of LAT-1 Expression in Esophageal Tissues Using Tissue Microarray.
Light Moderate Intense Total
Barrett’s metaplasia 1/11 (9.1%) 0/11 0/11 1/11 (9.1%)
Dysplasia 1/8 (12.5%) 0/8 0/8 1/8 (12.5%)
Esophageal adenocarcinoma 10/64 (15.6%) 10/64 (15.6%) 4/64 (6.3%) 24/64 (37.5%)
Lymph node metastases 1/8 (12.5%) 3/8 (37.5%) 0/8 4/8 (50%)
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Figure 2. Tissue microarray immunohistochemistry showing (A) light staining of LAT-1 in a sample of normal esophagus; (B) moderate staining in a sample of
dysplastic Barrett’s mucosa; and (C and D) intense staining in two esophageal adenocarcinoma samples. Intense staining of ASCT-1 was found in (E) normal
esophagus, (F) Barrett’s metaplasia, (G) Barrett’s dysplasia, and (H) esophageal adenocarcinoma. Arrows indicate esophageal mucosa. Original magnifications,
200. Sections were counterstained with hematoxylin.
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Esophageal Cell Lines Are Sensitive to Therapeutic
Doses of Melphalan
The esophageal adenocarcinoma cell lines, Bic-1 and
Seg-1, as well as an SV-40–immortalized esophageal squa-
mous cell line, Het-1A, were sensitive to therapeutic doses of
melphalan (5–25 mM) [29] with significant decreases in total
cell number and the ratio of live to dead cells (P < .001)
(Figure 4). Simultaneous treatment with the competitive
inhibitor, BCH (5 mM), decreased sensitivity to 5 mM mel-
phalan with total cell numbers and ratio of live to dead cells
significantly greater than control cultures (P < .05) (Figure 5).
Treatment with BCH alone did not result in any significant
differences in total cell number or ratio of live to dead cells.
In addition, confluent cultures of Seg-1 and Het-1A had a
marked decrease in LAT-1 protein expression as deter-
mined by Western blot analysis (Figure 6) and were signif-
icantly less sensitive to treatment with melphalan (P < .05)
(Figure 7).
LAT-1 Expression Is Maintained in Cell Lines Grown
In Vivo
Two esophageal adenocarcinoma cell lines, Seg-1 and
Bic-1, were injected in the flank of athymic nude mice.
Immunohistochemical analysis could not be performed be-
cause the only commercially available anti–LAT-1 antibody
is also produced in mice. However, using a semiquantitative
technique with ImageQuant 1.2 normalizing LAT-1 mRNA
expression to GAPDH after RT-PCR (Figure 8), LAT-1
mRNA expression was found to be maintained at relatively
high levels in tumors derived from Seg-1 (75% of cell culture
levels) and Bic-1 (95% of cell culture levels).
Discussion
LAT-1 is a member of the transport system L and is a
sodium-independent, high-affinity transporter of large,
branched-chain and aromatic, neutral amino acids [1].
LAT-1 is a hydrophobic protein composed of 507 amino
acids with 12 transmembrane domains and a predicted
molecular mass of 55 kDa [30]. LAT-1, like other light chain
subunits of the heterodimeric amino acid transporters includ-
ing LAT-2, y+LAT-1, y+LAT-2, xCT, and asc-1, is not able to
transport amino acids on its own but must associate with the
type II membrane glycoprotein 4F2 heavy chain (4F2hc) to
be functional [2]. Although 4F2hc expression is ubiquitous,
LAT-1 is normally expressed in fetal liver, bone marrow,
brain, placenta, and testes [2,5].
The heterodimeric amino acid transporters have a variety
of transport properties. LAT-1 transports large, neutral
amino acids such as tryptophan, phenylalanine, leucine,
Table 2. Immunohistochemical Analysis of ASCT-1 Expression in Esophageal Tissues Using Tissue Microarray.
Light Moderate Intense Total
Barrett’s metaplasia 2/11 (18.2%) 3/11 (27.3%) 6/11 (54.5%) 11/11 (100%)
Dysplasia 0/11 4/11 (36.4%) 7/11 (63.6%) 11/11 (100%)
Esophageal adenocarcinoma 27/64 (42.2%) 25/64 (39%) 10/64 (15.6%) 62/64 (96.9%)
Lymph node metastases 1/8 (12.5%) 3/8 (37.5%) 2/8 (25%) 6/8 (75%)
Figure 3. Western blot analysis shows (A) high levels of expression of LAT-1
(arrow, 55 kDa) in esophageal adenocarcinoma sample D48-T and moderate
amounts in S92-T. A lower amount of LAT-1 protein is seen in the esophageal
adenocarcinoma samples C55-T, S43-T, S36-T, and S68-T, as well as the
Barrett’s mucosa sample D48-B. (B) Nine esophageal cell lines showing
expression of LAT-1 (arrow, 55 kDa) in all cell lines including Het-1A, a
squamous cell line, and S23-B, derived from Barrett’s mucosa. (C) ASCT-1
(arrow, 55–70 kDa) expression in nine esophageal cell lines including
esophageal adenocarcinoma–derived Bic-1, Seg-1, H00-T, and Flo-1 as well
as the Barrett’smucosa-derivedS23-B. Smaller amounts of ASCT-1 protein are
seen in the esophageal adenocarcinoma cell line, L65-T, and the squamous cell
line, Het-1A. Highermolecular weight immunoreactive bands were also present
in all samples. -Actin expression was used as a loading control.
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and histidine with a high affinity (Km = f15–50 mM) and is
not affected by pH [2,5,31–33]. LAT-1 has a lower affinity
(Km =f150–200 mM) for L-glutamine and L-asparagine and
is also able to transport D-amino acids such as D-leucine and
D-phenylalanine [5]. LAT-1 mediates an exchange of amino
acids, and Yanagida et al. [5] have hypothesized that the net
influx of amino acids is mediated by an efflux of L-glutamine,
which is present at high levels intracellularly. Although
LAT-1 transports neutral amino acids, it has been classified
with several cationic amino acid transporters in solute car-
rier family 7 and is officially identified as SLC7A5 [34].
LAT-1 has been associated with growth, proliferation, and
tissue development [2–4]. Also identified as CD98, the
heterodimeric complex of LAT-1 and 4F2hc is also involved
in lymphocyte activation [35,36], and upregulation of CD98
results in tumorigenicity of Balb3T3 fibroblast cells in nude
mice [37]. The rat LAT-1 amino acid sequence was found to
have 100% identity with the rat integral membrane protein
E16 (TA1), which is a highly conserved oncofetal protein
involved in carcinogenesis and cell activation [30]. LAT-1 has
been found to be highly expressed in cultured cells and
malignant tumors, and overexpression of LAT-1 has been
proposed as a mechanism allowing continuous cell growth in
tumor cells [2–5]. All tumor cell lines examined by Yanagida
et al. [5] expressed LAT-1 including bladder, small cell lung,
cervical, and teratocarcinoma cells. In addition, Ohkame
et al. [6] showed a significant relationship between the
Figure 4. Two esophageal adenocarcinoma–derived cell lines, Bic-1 and
Seg-1, as well as an esophageal squamous cell line, Het-1A, were treated
with therapeutic doses of melphalan for 4 hours followed by a 48-hour
incubation in fresh media. All three cell lines were sensitive to melphalan, with
significant decreases in the ratio of live to dead cells and total cell number
after treatment. All experiments were repeated in triplicate, with error bars
indicating maximum and minimum values.
Figure 5. Two esophageal adenocarcinoma–derived cell lines, Bic-1 and
Seg-1, and an esophageal squamous cell line, Het-1A, were treated
simultaneously with the competitive inhibitor, BCH, and 5 M melphalan for
4 hours followed by a 48-hour incubation in fresh media. Sensitivity to
melphalan was significantly decreased as determined by the ratio of live to
dead cells and the total cell number. All experiments were repeated in
triplicate, with error bars indicating maximum and minimum values.
BCH = 2-aminobicyclo-(2,1,1)-heptane-2-carboxylic acid.
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expression of LAT-1 at the protein level and the size of
hepatic nodules in a model of rat colon carcinoma.
To our knowledge, LAT-1 expression has not been pre-
viously described in esophageal adenocarcinoma. In the
current study, LAT-1 mRNA overexpression was found in
87.5% (7/8) of stage I and stage II esophageal adenocarci-
nomas and was confirmed in 100% (28/28) of esophageal
adenocarcinomas between 3- and 38-fold higher than the
levels found in Barrett’s metaplasia. Meanwhile, LAT-1 pro-
tein expression was found in 37.5% (24/64) of esophageal
adenocarcinomas (Table 1) using immunohistochemistry of
TMA. Differences in expression at the mRNA and protein
levels have been reported in the literature for other genes.
Our laboratory has previously described the discordance
between protein and mRNA expression in lung adenocarci-
noma [38]. This difference in expression may be the result
of several factors. LAT-1 may be posttranscriptionally regu-
lated through changes in mRNA stability [39], transcript
localization [40], or translational efficiency. Differences in
expression may also be due to the rate of LAT-1 protein
degradation in different samples. In addition, the discor-
dance in mRNA and protein expression may be partially
due to differences in sensitivity between mRNA-based and
antibody-based assays such as immunohistochemistry.
Although low levels of LAT-1 protein were present in
Barrett’s metaplasia (1/11), dysplasia (1/8), and a normal
esophageal sample on immunohistochemistry, much higher
levels were found in tumor tissues, with moderate to intense
staining seen in 21.9% (14/64) of esophageal adenocarci-
nomas (Figure 2, C and D). All esophageal cell lines in
this study including those derived from esophageal adeno-
carcinoma, Barrett’s metaplasia, and normal squamous epi-
thelium expressed LAT-1 protein on Western blot analysis
(Figure 3B) consistent with previous reports that cultured
Figure 6. Confluent cultures (Seg-1 Conf and Het-1A Conf) showed markedly
decreased LAT-1 (arrow, 55 kDa) protein expression by Western blot
analysis of the esophageal adenocarcinoma–derived Seg-1 as well as the
esophageal squamous cell line, Het-1A. -Actin expression was used as a
loading control.
Figure 7. Confluent cultures of the esophageal adenocarcinoma–derived
Seg-1 and the esophageal squamous cell line, Het-1A, were treated with
therapeutic doses of melphalan for 4 hours followed by a 48-hour incubation
in fresh media. Both cell lines were significantly less sensitive to treatment
with melphalan as determined by the ratio of live to dead cells and total cell
number. All experiments were repeated in triplicate, with error bars indicating
maximum and minimum values.
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cells express high levels of LAT-1 [2–5]. On Western blot
analysis, LAT-1 was identified as a 55-kDa protein, which is
consistent with its predicted molecular weight. Although
LAT-1 protein has been described as a 35- to 45-kDa protein
on SDS-PAGE [2,5,33], Okamoto et al. [41] also reported a
larger 50-kDa band in placental tissues on Western blot
analysis, which was confirmed using a blocking peptide.
We have also confirmed the size of the LAT-1 band using a
second anti–LAT-1 polyclonal antibody (Serotec, Oxford,
UK). This size discrepancy may be due to posttranslational
modifications such as glycosylation [30].
The expression of another amino acid transporter,
ASCT-1, has been described in esophageal adenocarci-
noma by Younes et al. [28]. ASCT-1 is a transporter of small
neutral amino acids and has been reported to be overex-
pressed in the majority of esophageal adenocarcinomas.
The results of the current study show ASCT-1 protein stain-
ing in 96.9% (62/64) of esophageal adenocarcinoma sam-
ples (Table 2) and protein expression in several esophageal
adenocarcinoma cell lines including Bic-1, Flo-1, Seg-1, and
H00-T (Figure 3C). However, expression of this transporter
was also found in 100% of Barrett’s metaplasia (11/11) and
dysplasia (11/11) samples (Table 2; Figure 2, F and G), as
well as the Barrett’s mucosa-derived cell line, S23-B (Figure
3C). In addition, the most intense ASCT-1 staining was seen
in Barrett’s metaplasia and dysplasia samples. Although
ASCT-1 is expressed in esophageal adenocarcinomas, its
expression may be reflective of the cell type of origin, rather
than a critical role in the growth, proliferation, and develop-
ment of esophageal adenocarcinoma.
An interesting characteristic of the LAT-1 transporter is its
broad substrate selectivity, allowing it to transport amino
acid–related compounds including L-DOPA, thyroid hor-
mones, gabapentin, and the chemotherapeutic agent, mel-
phalan [1,7–11]. Melphalan, or L-phenylalanine mustard, is
an alkylating agent that was first synthesized in 1953 [42].
Vistica et al. [43] demonstrated that the uptake of melphalan
is an active process with an approximately 10-fold difference
between intracellular and extracellular levels. Goldenberg
et al. [8] identified two amino acid carrier systems involved in
the uptake of melphalan. One is a system L sodium-inde-
pendent transporter inhibited by BCH, whereas the other is
sodium-dependent, inhibited by alanine, serine, and cyste-
ine, and appears to be a system ASC-like amino acid
transporter.
LAT-1 upregulation in tumor cells has been identified as
one of the major routes in the uptake of melphalan [5].
Begleiter et al. [44] have reported a Km of 80 mM for system
L–mediated uptake of melphalan, and in a Xenopus oocyte
expression system, 100 mM melphalan was able to inhibit
50% of the LAT-1–mediated uptake of [14C]phenylalanine
[12]. In addition, the level of system L amino acid transporter
activity in tumor cells has been reported to correlate with
melphalan sensitivity [13,14]. Downregulation of LAT-1
(CD98) has also been found in melphalan-resistant myeloma
cells with reduced melphalan uptake [13].
Melphalan has been utilized in the treatment of multiple
myeloma, ovarian and breast carcinoma, sarcoma, and
metastatic melanoma, and the most common side effect is
bone marrow suppression. To our knowledge, melphalan
has not been previously described in the treatment of esoph-
ageal adenocarcinomas. We hypothesized that esophageal
adenocarcinoma cells expressing LAT-1 would be sensitive
to melphalan. To evaluate the sensitivity of esophageal cells
to melphalan, two esophageal adenocarcinoma cell lines,
Bic-1 and Seg-1, and an esophageal squamous cell line,
Het-1A, were treated with 5 to 25 mM melphalan. Although
doses as high as 50 to 100 mM [12,23] have been used in cell
culture studies in the literature, this dosage range was cho-
sen as more clinically relevant. According to Anderson et al.
[29], patient plasma levels range from 2.3 to 54 mM, with
higher doses being used for bone marrow ablative therapy.
The esophageal adenocarcinoma–derived cell lines,
Bic-1 and Seg-1, as well as the squamous cell line,
Het-1A, expressed LAT-1 (Figure 3) and were sensitive
to therapeutic doses of melphalan. Significant decreases in
total cell number and the ratio of live to dead cells were seen
after a single treatment with 5 to 25 mMmelphalan (P < .001)
(Figure 4). A dose response was found, with total cell
numbers decreased up to 75% and the ratio of live to dead
cells up to 69% after treatment with 25 mM melphalan.
Simultaneous treatment with BCH (5 mM), a competitive
inhibitor of the system L amino acid transporter, decreased
sensitivity to 5 mMmelphalan, with total cell numbers and the
ratio of live to dead cells significantly greater than control
cultures (P < .05; Figure 5). By inhibiting uptake through
LAT-1, BCH is able to decrease sensitivity to melphalan,
confirming the importance of LAT-1 in the uptake of melpha-
lan as previously reported [5,12–14]. Treatment with BCH
alone did not result in significant differences in cell number or
the ratio of live to dead cells, indicating that either adequate
LAT-1 function remains despite inhibition with BCH, or that
other amino acid transport systems are able to compensate,
providing nutrients to support continuous cell growth and
proliferation.
Figure 8. LAT-1 mRNA expression is maintained in tumors derived from two
esophageal adenocarcinoma–derived cell lines, Seg-1 and Bic-1, after
injection into nude mice as determined by RT-PCR. GAPDH was coamplified
as an internal control for each reaction. M=size marker; CC=cell culture;
NM=tumors grown in nude mice.
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Although proliferating esophageal squamous Het-1A
cells express LAT-1 and are sensitive to melphalan, con-
fluent cultures may be a more accurate reflection of the
majority of esophageal squamous epithelium in vivo and
were significantly less sensitive to treatment with melphalan
(P < .001; Figure 7). Total cell number and the ratio of live to
dead cells in confluent cultures were approximately 40% to
50% greater when compared to 70% confluent cultures
treated with 5 mM melphalan. Although confluent cells are
no longer rapidly proliferating and may be expected to be
less sensitive to a variety of chemotherapeutic agents due
to their decreased growth rate, melphalan, like most bifunc-
tional alkylating agents, is cell cycle– independent and is
active against both resting and rapidly dividing cells [45]. An
alternative mechanism for lower melphalan sensitivity in
confluent Het-1A cells is a decrease in the uptake of
melphalan due to the markedly reduced levels of LAT-1
protein seen on Western blot analysis (Figure 6). These
findings agree with results previously reported by Blosmanis
et al. [46] evaluating melphalan sensitivity of BALB/c 3T3
fibroblasts. Proliferating cells were found to have a three-
fold higher uptake of melphalan than nondividing cells with a
progressive decrease in uptake the longer cells were kept in
the resting phase. They conclude that the lower cytotoxic
activity of melphalan in resting cells was due to the de-
creased level of melphalan uptake.
LAT-1 is highly expressed in a subset of esophageal
adenocarcinomas, and Barrett’s adenocarcinoma cell lines
expressing LAT-1 are sensitive to melphalan. These results
suggest that treatment with amino acid nitrogen mustards
like melphalan may be beneficial in a subset of patients with
Barrett’s adenocarcinomas expressing LAT-1. This study
also shows that LAT-1 mRNA expression is maintained in
tumors derived from two esophageal adenocarcinoma cell
lines, Seg-1 and Bic-1, after injection in the flank of athymic
nude mice as determined by RT-PCR (Figure 8). These
findings provide a potential animal model that could be used
to further study treatment with melphalan in hopes of finding
an effective therapy against esophageal adenocarcinoma,
for which few successful treatments are currently available.
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